Safety and immunogenicity of the ChAdOx1 nCoV-19 ( AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial (vol 8, pg e568, 2021)